关键词：甲型H1N1流感；人类感染性疾病；正粘病毒科；高危人群；预防接种
摘 要：H1N1 influenza (zoonotic) is an infectious disease in humans caused by the H1N1 virus. The H1N1 virus infects the nose, throat, and lungs of the host. It is an RNA virus and a type of influenza A virus belonging to the Orthomyxoviridae family. Influenza A viruses can infect different animal species such as humans, swine, birds, seals, and horses. On the basis of the antigenicity of their surface glycoproteins, influenza A viruses can be subdivided into neuraminidase and hemagglutinin. The hemagglutinin component is used by the virus to bind to host cell receptors, thereby facilitating viral entry into the host cell. The neuraminidase protein enzymatically cleaves terminal sialic acid residues from mucins, thereby allowing the virus to reach underlying cells in the respiratory tract. The elderly, young children, and people with medical conditions such as liver disorders, blood disorders, kidney disorders, chronic lung disease, asthma, and neurodevelopmental and neurological conditions are more susceptible to the infection. Influenza vaccines are administered for active immunization against the influenza virus, conferring protection against the disease. Vaccination of high-risk groups prevents unnecessary hospitalizations and premature deaths because of the disease.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Market Segmentation by Route of

Administration

08. WHO Recommendation

09. Key H1N1 Virus Vaccines for 2013-2014 Flu

Season in US

10. H1N1 Virus Vaccines Approved in EU

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Market Share Analysis 2013

19.3 Other Prominent Vendors

20. Key Vendor Analysis

20.1 AstraZeneca

20.1.1 Key Facts

20.1.2 Business Description

20.1.3 Business Segmentation

20.1.4 Business Strategy

20.1.5 Revenue by Business Segmentation

20.1.6 Revenue Comparison 2011-2013

20.1.7 Sales Revenue by Geographical Segmentation

20.1.8 Key Developments

20.1.9 SWOT Analysis

20.2 GlaxoSmithKline

20.2.1 Key Facts

20.2.2 Business Overview

20.2.3 Business Segmentation

20.2.4 Business Segmentation by Revenue 2012 and 2013

20.2.5 Sales by Geography

20.2.6 Pipeline Products

20.2.7 Business Strategy

20.2.8 Key Information

20.2.9 SWOT Analysis

20.3 Novartis

20.3.1 Key Facts

20.3.2 Business Overview

20.3.3 Business Segmentation by Revenue 2013

20.3.4 Business Segmentation by Revenue 2012 and 2013

20.3.5 Sales by Geography

20.3.6 Business Strategy

20.3.7 Key Developments

20.3.8 SWOT Analysis

20.4 Sanofi Pasteur

20.4.1 Key Facts

20.4.2 Business Overview

20.4.3 Business Strategy

20.4.4 Recent Developments

20.4.5 SWOT Analysis

21. Other Reports in this Series